Could a simple injection stop type 1 diabetes before it starts?
NCT ID NCT05683990
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests a drug called Diamyd, given as injections into lymph nodes, to see if it is safe and can prevent type 1 diabetes in children aged 8 to 17 who are at high risk. Only 5 participants are enrolled, and the study focuses on safety and whether the drug can stop the disease from progressing. It is an early step, not a proven prevention.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Diamyd (a drug injected into lymph nodes to train the immune system)
What this could lead to
If it works, this could point toward a way to delay or prevent type 1 diabetes in children who are genetically at risk.
What could go wrong
This is a very small early trial with only 5 participants, so results may not apply broadly. The drug could cause side effects or fail to stop diabetes progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREVENTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lund University/CRC, Skåne University Hospital,
Malmö, Sweden